ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClotting factor prophylaxis remains the most prescribed standard-of-care treatment for people with haemophilia (PwH). Prophylaxis prevents bleeds, joint damage, and improves quality of life (QoL). Its success depends on treatment adherence, consisting of socioeconomic, behavioural, and disease- or therapy-related factors.
aimTo identify determinants of clotting factor prophylaxis adherence among PwH followed at a Hemophilia Treatment Center (HTC) in Brazil.
methodsA cross-sectional study was conducted at a Brazilian HTC in June-October/2022. Eligible participants were PwH A or B without inhibitors and on clotting factor prophylaxis, aged ≥ 14 years. Demographic, clinical, and therapeutic data were collected from records and interviews. Health-related QoL was assessed by the SF-36 questionnaire. Adherence was assessed using the Brazilian validated Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro) questionnaire.
resultsAmong 78 PwH (median age 30 years), 70 (90%) had severe haemophilia, 46 (59%) reported joint impairment, and 67 (86%) infused 3 times/week. Median SF-36 score was 70.3 (interquartile range [IQR] 57.3-83.3). Median VERITAS-Pro score was 44.0 (IQR 35.0-50.0), resulting in 70 (90%) adherent PwH. SF-36 score was not correlated with VERITAS-Pro. Clotting factor prophylaxis adherence was associated with having haemophilia A (p = 0.012) and infusing factor >2 times weekly (p = 0.008), and inversely correlated with prophylaxis duration (r = 0.317 [weak clinical correlation]; p = 0.005), and directly correlated with SF-36 domain "Mental health" (r = -0.304 [weak clinical correlation]; p = 0.007).
conclusionThe main factors determining adherence to clotting factor prophylaxis were having haemophilia A, receiving factor infusions more than twice weekly, having a shorter duration of prophylaxis, and good mental health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.